How Much Weight Loss Can You Expect After 1 Month on Wegovy?

Why is weight loss in the first month on Wegovy typically modest?

Wegovy's titration schedule exists for a reason. Treatment opens at 0.25 mg weekly, which is not a therapeutic weight-loss dose, it is there to let your gut adjust to semaglutide and reduce the likelihood of nausea or vomiting that can occur at higher levels. Your prescriber then steps the dose upward roughly every four weeks: 0.5 mg, 1.0 mg, 1.7 mg, and eventually 2.4 mg, which is the standard maintenance dose. The newer 7.2 mg dose, approved by the MHRA in April 2026, sits above that for eligible patients.

By the end of month one you are likely still on 0.25 mg or just moving to 0.5 mg. At that level, appetite suppression is partial at best. Many people notice some reduction in hunger, and a few drop meaningful weight in week one simply from eating less. Others see the scales barely shift. Both outcomes are normal at this stage. The medicine is doing preparatory work, not its full job yet.

One question our prescribers hear regularly is whether a quiet first month means the treatment is not working. The short answer is: almost certainly not. Give it time, and give it the full dose.

What does the clinical trial evidence say about early semaglutide weight loss?

The STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity over 68 weeks on semaglutide 2.4 mg alongside lifestyle support. The average weight reduction across the full trial was around 15%. Month-by-month breakdown from phase 3 data consistently shows the sharpest rate of loss occurring between months three and nine, once participants reach and sustain the maintenance dose, and if you want to understand what that pivotal period looks like, the Wegovy 3 month weight loss page explains what to expect as the dose builds toward its therapeutic level. Month one, on the starter dose, accounts for a small fraction of that eventual total.

That pattern matters if you are three weeks in and feel discouraged. The trajectory on Wegovy is not linear and it does not front-load results. If you want a fuller picture of how outcomes build, the month-by-month Wegovy weight loss breakdown goes through each phase of treatment in detail. What the trials do confirm is that sticking with the titration schedule (eating well, staying active, not skipping doses) shapes the eventual result far more than what the scales say at day 30.

People sometimes time their start around a milestone: a new month, a Monday, even a payday because the prescription is in budget. Whatever brings you to month one, the clinical picture is the same: slow build, then real progress.

What if there is no weight loss after 1 month on Wegovy?

Very little weight change in month one is common and is not grounds to stop or panic. What matters clinically is what happens at six months, once you have been on the maintenance dose (2.4 mg or higher) for a sustained period. NICE's guidance on semaglutide (TA875) recommends reviewing whether to continue treatment if a person has not achieved at least 5% weight loss after six months at the maintenance dose, month one is not part of that calculation.

There are genuine reasons some people see no change even beyond month one: calorie intake not adapting to reduced appetite signals, GI side effects disrupting eating patterns in ways that offset each other, or simply the biology of a slow-starter response. A few people do experience nausea severe enough that they eat less but also feel too unwell to function, in that case, speak to your prescriber rather than pushing through. Dose adjustments are possible and exist precisely for this situation.

What you should not do is compare your month-one results with someone else's. Starting weight, metabolic rate, adherence to lifestyle changes and individual response to GLP-1 medicines vary enormously. If you are curious about the fuller arc of treatment, the Wegovy six-month weight loss page covers what the evidence shows at that more clinically meaningful milestone. For a closer look at what happens right after that initial phase, the weight loss after the first month page picks up where this one leaves off.

Is Wegovy the right choice for you, and how do you get a prescription?

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds may apply for some ethnic backgrounds under UK guidance. A prescriber assesses the full picture (your health history, other medicines, contraindications) before any prescription is issued. BMI alone does not guarantee approval.

For context on where to access Wegovy in the UK and the process involved, that page covers both NHS and private routes. On the NHS, Wegovy is available through specialist weight management services under NICE TA875, though waiting lists can be long. Privately, a regulated online pharmacy with a GPhC-registered prescriber is a legal alternative for people who do not meet the current NHS criteria or prefer not to wait. You can verify any UK online pharmacy on the GPhC pharmacy register before submitting any personal information.

If you are weighing up semaglutide against other licensed options, the semaglutide overview and the broader weight-loss treatment page set out how each medicine works and what the clinical assessment involves. Treatment for a prescription medicine should always start with a proper clinical conversation, not a quick decision based on month-one expectations alone.